Slides
Page 1
Main palette 213-19-23 64-64-64 124-124-123 218-218-218 242-242-242 255-214-24 224-50-17 154-25-21 222-119-162 150-51-121 72-39-124 130-193-122 0-150-77 0-108-70 136-199-216 0-115-140 29-67-111 0-159-178 Secondary palette RECORDATI «UNLOCKING THE POTENTIAL IN RARE DISEASES» J.P . Morgan Healthcare Conference Rob Koremans, CEO January 14, 2026
Page 2
2 Main palette 213-19-23 64-64-64 124-124-123 218-218-218 242-242-242 255-214-24 224-50-17 154-25-21 222-119-162 150-51-121 72-39-124 130-193-122 0-150-77 0-108-70 136-199-216 0-115-140 29-67-111 0-159-178 Secondary palette COMPANY DECLARATIONS, DISCLAIMERS AND PROFILE Statements contained in this presentation, other than historical facts, are “forward-looking statements” (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable by Management. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company’s control. These risks and uncertainties include among other things, the uncertainties inherent in pharmaceutical marketing and development, impact of decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug or biological application that may be filed as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of our products, the future approval and commercial success of therapeutic alternatives, Recordati’s ability to benefit from external growth opportunities, to complete capital markets or other transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and capital market conditions, cost containment initiatives by payors of medicines and subsequent changes thereto, and the impact that pandemics, political disruption or armed conflicts or other global crises may have on our business. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company’s activities and are not intended to indicate the advisability of administering any product in any particular instance. Recordati (Reuters RECI.MI, Bloomberg REC IM) is an international pharmaceutical group listed on the Italian Stock Exchange (ISIN IT 0003828271) uniquely structured to bring treatment across specialty and primary care and rare diseases. We believe that health, and the opportunity to live life to the fullest, is a right, not a privilege. We want to support people in unlocking the full potential of their lives. We have fully integrated operations across research & development, chemical and finished product manufacturing through to commercialization and licensing. Established in 1926, Recordati operates in approximately 150 countries across EMEA, Americas and APAC regions. At the end of 2023, Recordati employed over 4,450 people and consolidated revenue of € 2,082.3 million. For more information, please visit www.recordati.com Offices: Recordati S.p.A. Via M. Civitali 1 20148 Milano, Italy Website: www.recordati.com